默沙东的男性HPV疫苗,救不了智飞生物。

医药财经
11 Jan

默沙东与智飞生物在疫苗供销领域合作多年。然而,当默沙东宣布其四价HPV疫苗佳达修获批用于9-26岁男性接种,成为中国首个获批男性HPV疫苗时,这一消息并未给智飞生物带来预期中的曙光。相反,这一举措或许只是进一步加剧了智飞生物面临的挑战。默沙东的男性HPV疫苗:抢占先机默沙东的四价HPV疫苗佳达修覆盖HPV6、11、16、18四种病毒分型,可预防肛门癌、生殖器疣等疾病。此次获批男性适应证,意味着...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10